Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1385–1391. doi: 10.1038/sj.bjc.6693404

Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis

A Scorilas 1,2, T Trangas 1, J Yotis 2, C Pateras 3, M Talieri 1
PMCID: PMC2362965  PMID: 10604737

Abstract

C-myc and c-erbB-2 amplification and/or overexpression as well as total cathepsin-D (CD) concentration have been reported to be associated with poor prognosis in breast cancer. The prognostic significance, however, remains somewhat controversial, partly because of discrepancies among the different methodologies used. We determined the amplification and overexpression of c-myc oncogene in 152 breast cancer patients and examined its prognostic value in relation to c-erbB-2 amplification and overexpression, high concentration of CD (≥ 60 pmol mg–1 protein) and standard clinicopathological prognostic factors of the disease. High CD concentration, as well as c-myc amplification and overexpression, proved to be the best of the new variables examined for prediction of early relapse (ER; before 3 years). After multivariate analysis only CD remained significant, which suggests that the prognostic power of these variables is similar. Using univariate analysis we proved that c-myc amplification and overexpression were highly significant for disease-free survival (DFS) (P = 0.0016 and P = 0.0001 respectively) and overall survival (OS) (P < 0.0001 and P = 0.0095 respectively), although by multivariate analysis c-myc overexpression was statistically significant only for DFS (P = 0.0001) and c-myc amplification only for OS (P = 0.0006). With regard to c-erbB-2, only its overexpression appeared to be significant for DFS and OS, although after multivariate analysis its prognostic power was weaker (P = 0.030 and P = 0.024 respectively). c-myc amplification and overexpression exhibited a tendency for locoregional recurrence (LRR) (P = 0.0024 and P = 0.0075 respectively), however, their prognostic value was lower after multivariate analysis and only CD remained significant. © 1999 Cancer Research Campaign

Keywords: c-myc, c-erbB-2, cathepsin-D, early relapse, relapse-free survival, overall survival, locoregional recurrence, breast cancer

Full Text

The Full Text of this article is available as a PDF (109.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcon R. M., Rupnow B. A., Graeber T. G., Knox S. J., Giaccia A. J. Modulation of c-Myc activity and apoptosis in vivo. Cancer Res. 1996 Oct 1;56(19):4315–4319. [PubMed] [Google Scholar]
  2. Alitalo K., Schwab M. Oncogene amplification in tumor cells. Adv Cancer Res. 1986;47:235–281. doi: 10.1016/s0065-230x(08)60201-8. [DOI] [PubMed] [Google Scholar]
  3. Allred D. C., Harvey J. M., Berardo M., Clark G. M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155–168. [PubMed] [Google Scholar]
  4. Ambler L., Peters G. E. An immunospecific enzyme assay for horseradish peroxidase. Anal Biochem. 1984 Feb;137(1):66–68. doi: 10.1016/0003-2697(84)90347-6. [DOI] [PubMed] [Google Scholar]
  5. Ben-Yosef T., Yanuka O., Halle D., Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998 Jul 16;17(2):165–171. doi: 10.1038/sj.onc.1201939. [DOI] [PubMed] [Google Scholar]
  6. Berns E. M., Klijn J. G., Smid M., van Staveren I. L., Look M. P., van Putten W. L., Foekens J. A. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer. 1996 Jul;16(3):170–179. doi: 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  7. Berns E. M., Klijn J. G., van Putten W. L., van Staveren I. L., Portengen H., Foekens J. A. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992 Mar 1;52(5):1107–1113. [PubMed] [Google Scholar]
  8. Berns E. M., Klijn J. G., van Staveren I. L., Portengen H., Noordegraaf E., Foekens J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28(2-3):697–700. doi: 10.1016/s0959-8049(05)80129-7. [DOI] [PubMed] [Google Scholar]
  9. Bland K. I., Konstadoulakis M. M., Vezeridis M. P., Wanebo H. J. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg. 1995 Jun;221(6):706–720. doi: 10.1097/00000658-199506000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brenn T., Arnesen E. Selecting risk factors: a comparison of discriminant analysis, logistic regression and Cox's regression model using data from the Tromsø Heart Study. Stat Med. 1985 Oct-Dec;4(4):413–423. doi: 10.1002/sim.4780040403. [DOI] [PubMed] [Google Scholar]
  11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  12. Dati C., Antoniotti S., Taverna D., Perroteau I., De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene. 1990 Jul;5(7):1001–1006. [PubMed] [Google Scholar]
  13. Dubik D., Shiu R. P. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem. 1988 Sep 5;263(25):12705–12708. [PubMed] [Google Scholar]
  14. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M. H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834–4838. doi: 10.1073/pnas.83.13.4834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ferrandina G., Scambia G., Bardelli F., Benedetti Panici P., Mancuso S., Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer. 1997;76(5):661–666. doi: 10.1038/bjc.1997.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Garcia I., Dietrich P. Y., Aapro M., Vauthier G., Vadas L., Engel E. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 1989 Dec 1;49(23):6675–6679. [PubMed] [Google Scholar]
  17. Guérin M., Barrois M., Terrier M. J., Spielmann M., Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988;3(1):21–31. [PubMed] [Google Scholar]
  18. Kreipe H., Feist H., Fischer L., Felgner J., Heidorn K., Mettler L., Parwaresch R. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res. 1993 Apr 15;53(8):1956–1961. [PubMed] [Google Scholar]
  19. Lönn U., Lönn S., Nilsson B., Stenkvist B. Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer. 1995 Jun 1;75(11):2681–2687. doi: 10.1002/1097-0142(19950601)75:11<2681::aid-cncr2820751107>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  20. Lösch A., Tempfer C., Kohlberger P., Joura E. A., Denk M., Zajic B., Breitenecker G., Kainz C. Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer. Br J Cancer. 1998 Jul;78(2):205–209. doi: 10.1038/bjc.1998.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Osborne C. K. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol. 1992 May;10(5):679–682. doi: 10.1200/JCO.1992.10.5.679. [DOI] [PubMed] [Google Scholar]
  22. Pavelic Z. P., Pavelic L., Lower E. E., Gapany M., Gapany S., Barker E. A., Preisler H. D. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 1992 May 1;52(9):2597–2602. [PubMed] [Google Scholar]
  23. Pertschuk L. P., Feldman J. G., Kim D. S., Nayeri K., Eisenberg K. B., Carter A. C., Thelmo W. T., Rhong Z. T., Benn P., Grossman A. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer. 1993 Jan 1;71(1):162–171. doi: 10.1002/1097-0142(19930101)71:1<162::aid-cncr2820710126>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  24. Pietiläinen T., Lipponen P., Aaltomaa S., Eskelinen M., Kosma V. M., Syrjänen K. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res. 1995 May-Jun;15(3):959–964. [PubMed] [Google Scholar]
  25. Prall O. W., Rogan E. M., Sutherland R. L. Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):169–174. doi: 10.1016/s0960-0760(98)00021-1. [DOI] [PubMed] [Google Scholar]
  26. Read L. D., Keith D., Jr, Slamon D. J., Katzenellenbogen B. S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 1990 Jul 1;50(13):3947–3951. [PubMed] [Google Scholar]
  27. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol. 1992;31(2):125–130. doi: 10.3109/02841869209088891. [DOI] [PubMed] [Google Scholar]
  28. Roux-Dosseto M., Romain S., Dussault N., Desideri C., Piana L., Bonnier P., Tubiana N., Martin P. M. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer. 1992;28A(10):1600–1604. doi: 10.1016/0959-8049(92)90050-c. [DOI] [PubMed] [Google Scholar]
  29. Santos G. F., Scott G. K., Lee W. M., Liu E., Benz C. Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem. 1988 Jul 15;263(20):9565–9568. [PubMed] [Google Scholar]
  30. Scorilas A., Yotis J., Gouriotis D., Keramopoulos A., Ampela K., Trangas T., Talieri M. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res. 1993 Sep-Oct;13(5C):1895–1900. [PubMed] [Google Scholar]
  31. Scorilas A., Yotis J., Pateras C., Trangas T., Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res. 1999 Apr;5(4):815–821. [PubMed] [Google Scholar]
  32. Scorilas A., Yotis J., Stravolemos K., Gouriotis D., Keramopoulos A., Ampela K., Talieri M., Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res. 1995 Jul-Aug;15(4):1543–1547. [PubMed] [Google Scholar]
  33. Sistonen L., Koskinen P. J., Lehväslaiho H., Lehtola L., Bravo R., Alitalo K. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells. Oncogene. 1990 Jun;5(6):815–821. [PubMed] [Google Scholar]
  34. Sjögren S., Inganäs M., Lindgren A., Holmberg L., Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998 Feb;16(2):462–469. doi: 10.1200/JCO.1998.16.2.462. [DOI] [PubMed] [Google Scholar]
  35. Spyratos F., Maudelonde T., Brouillet J. P., Brunet M., Defrenne A., Andrieu C., Hacene K., Desplaces A., Rouëssé J., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989 Nov 11;2(8672):1115–1118. doi: 10.1016/s0140-6736(89)91487-6. [DOI] [PubMed] [Google Scholar]
  36. Suen T. C., Hung M. C. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol Cell Biol. 1991 Jan;11(1):354–362. doi: 10.1128/mcb.11.1.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Thomas P. S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201–5205. doi: 10.1073/pnas.77.9.5201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Watson P. H., Singh R., Hole A. K. Influence of c-myc on the progression of human breast cancer. Curr Top Microbiol Immunol. 1996;213(Pt 2):267–283. doi: 10.1007/978-3-642-61109-4_13. [DOI] [PubMed] [Google Scholar]
  39. van der Burg B., van Selm-Miltenburg A. J., de Laat S. W., van Zoelen E. J. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol. 1989 Jul;64(2):223–228. doi: 10.1016/0303-7207(89)90149-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES